Zentalis Pharmaceuticals, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $0 | $67.4M | $0 | $0 | — |
| Research and development | $107.3M | $167.8M | $189.6M | $172.7M | $175.6M |
| Operating expenses | $152.8M | $258.6M | $299.5M | $227.3M | $216.5M |
| Operating income | -$152.8M | -$191.2M | -$299.5M | -$227.3M | -$216.5M |
| Pretax income | -$136.6M | -$165.7M | -$276.9M | -$221.3M | -$164.6M |
| Income tax expense | $442,000 | $177,000 | -$601,000 | -$469,000 | -$297,000 |
| Net income | -$137.1M | -$165.8M | -$292.2M | -$236.8M | -$158.7M |
| Balance Sheet | |||||
| Cash and equivalents | $36.0M | $33.9M | $28.0M | $43.1M | $59.7M |
| Current assets | $253.2M | $386.1M | $496.7M | $451.9M | $350.8M |
| Total assets | $289.0M | $430.3M | $551.7M | $539.3M | $454.5M |
| Current liabilities | $36.6M | $52.7M | $69.4M | $56.6M | $43.9M |
| Total liabilities | $72.8M | $93.2M | $114.3M | $105.3M | $90.0M |
| Stockholders' equity | $216.2M | $337.2M | $437.3M | $433.8M | $364.5M |
| Cash Flow Statement | |||||
| Cash from operations | -$125.2M | -$170.9M | -$207.8M | -$163.8M | -$154.1M |
| Depreciation and amortization | $739,000 | $1.3M | $1.4M | $1.4M | $544,000 |
| Stock-based compensation | $20.7M | $67.3M | $54.8M | $46.8M | $35.7M |
| Capital expenditure | $0 | $221,000 | $583,000 | $2.5M | $6.1M |
| Free cash flow | -$125.2M | -$171.1M | -$208.4M | -$166.3M | -$160.2M |
| Share repurchases | $10.0M | $0 | $0 | — | — |
| Impairments | $0 | $3.7M | $0 | $0 | $8.8M |
Shares outstanding 71.2M · Free float 62.6%
Annual filing data through FY ended December 31, 2025; float as of July 15, 2026.